Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the

Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the pric

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.99) per share which beat the analyst conse

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their secto

Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m

Adicet Bio NASDAQ: ACET outlined its near-term clinical priorities and upcoming data catalysts durin

Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their secto

The average of price targets set by Wall Street analysts indicates a potential upside of 319.6% in A

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.88) per share which beat the analyst conse

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the

HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and lo

Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the pric

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(2.94) per share which beat the analyst conse

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) has been assigned a consensus recommendation of "M

Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) have received a consensus rating of "Mod

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and ra

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report)'s share price crossed below its two hundred day mo

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant decline in shor

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) passed below its 200-day moving average during tra

Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing al

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalim

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant growth in short

Shares of Adicet Bio are trading lower after the clinical stage biotechnology company announced a on

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and ra

Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the pric

Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephri

Clinical data to date supports a potentially transformational approach to treating autoimmune diseas

Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $7 p

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.34) per share which missed the analyst con

HC Wainwright & Co. analyst Robert Burns assumes Adicet Bio (NASDAQ:ACET) with a Buy rating a

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.31) per share which beat the analyst conse

Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $7 p

Citizens Capital Markets analyst Reni Benjamin reiterates Adicet Bio (NASDAQ:ACET) from Market Pe

JMP Securities analyst Reni Benjamin reiterates Adicet Bio (NASDAQ:ACET) from Market Perform to M

Plans To Advance Phase 1 Trial Of ADI-001 Across Six Autoimmune Diseases With Preliminary Lupus Neph